🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to health experts.

A Global Challenge

Gonorrhoea infections are increasing around the world, with data suggesting more than 82 million instances each year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, escalating drug resistance and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Authorization

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone represents a major breakthrough in the treatment of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Results and Global Access

According to data released by a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which involves an injection and a pill. The research involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in many regions with limited resources.

Clinicians treating patients have shared hope. Access to a easy-to-administer therapy such as this is described as a "critical tool" for public health efforts. This is considered essential to lessen the impact of the illness for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.